Harbin Gloria Pharmaceuticals Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Harbin Gloria Pharmaceuticals Co., Ltd.
GloriaBio's Zimberelimab Experience Indicative Of China Commercial IO Challenges
As of October 2022, China's GloriaBio had reached less than 25% of the annual sales volume expected for its anti-PD-1 antibody zimberelimab and was set to miss its full-year target, forcing a CNY423m ($62m) impairment provision and illustrating how immuno-oncology fortunes can fluctuate in the country.
Younger Females' Cancer Incidence Increases Significantly In China
Latest data show a worrying public health trend that remains the top health concern in China despite surging COVID infections.
Pfizer, CStone Score China's Seventh Immuno-Oncology Approval
Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.
Wellness Industry News: Acting FDA Commissioner Named, Thorne Test Line Grows, Nitrosigine In Revel Energy, More
NCI's Sharpless named acting FDA head; Mannatech trims loss as costs grow; Nilo drinks to avoiding hangovers; Daoust leads Soylent Nutrition development, innovation; Viactiv in taller, narrower package; Revel Energy made with Nitrosigine; and Thorne has at-home tests for additional concerns.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Guangzhou Gloria Biosciences Co., Ltd.
- Yu Heng Pharmaceutical
- Shanghai Huatuo
- Ono (china)
- Harbin Dandelion Pharmaceutical Co., Ltd.,
- Harbin Yuheng Jingwei Pharmaceutical Development Co., Ltd.
- Pude Pharmaceutical, Beijing Podconley Pharmaceutical Technology & Development Co., Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.